Zobrazeno 1 - 10
of 35
pro vyhledávání: '"G. Yamaguti"'
Autor:
MC Ozelo, J Mahlangu, B Madan, J Mason, F Peyvandi, AV Drygalski, G Yamaguti-Hayakawa, TM Robinson, SW Pipe, TT Gener-Eigh
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 45, Iss , Pp S451-S452 (2023)
Aims: Valoctocogene roxaparvovec (AAV5-hFVIII-SQ) provides endogenous factor VIII (FVIII) production to prevent bleeding in people with severe hemophilia A. This study evaluated bleeding, FVIII activity and safety outcomes 3 years after receiving val
Externí odkaz:
https://doaj.org/article/073f51b8f2be4bc78410d269a66d55b0
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 6, Iss 3, Pp n/a-n/a (2022)
Abstract Hemophilia A and B are hereditary bleeding disorders, characterized by factor VIII or IX deficiencies, respectively. For many decades, prophylaxis with coagulation factor concentrates (replacement therapy) was the standard‐of‐care approa
Externí odkaz:
https://doaj.org/article/2eb5e873c9bf4ea7a913d1e4149da20e
Autor:
Alessandra N. L. Prezotti, Jéssica O. Frade-Guanaes, Gabriela G. Yamaguti-Hayakawa, Margareth C. Ozelo
Publikováno v:
Pharmaceuticals, Vol 15, Iss 8, p 911 (2022)
Anti-drug antibody (ADA) development is a significant complication in the treatment of several conditions. For decades, the mainstay of hemophilia A treatment was the replacement of deficient coagulation factor VIII (FVIII) to restore hemostasis, con
Externí odkaz:
https://doaj.org/article/2d71683a1efa44009d4be958ca6101ba
Publikováno v:
Exp Biol Med (Maywood)
Hemophilia A (factor VIII [FVIII] deficiency) and hemophilia B (factor IX [FIX] deficiency) are the X-linked recessive bleeding disorders that clinically manifest with recurrent bleeding, predominantly into muscles and joints. In its severe presentat
Autor:
Gabriela de França Delmoro, Marina Pereira Colella, Erich Vinicius De Paula, Elizio Chiacchio Ferraz Alves, Joyce Maria Annichino Bizzacchi, Fernanda Andrade Orsi, Gabriela G Yamaguti-Hayakawa
Publikováno v:
Journal of Thrombosis and Haemostasis
Dapsone has been used in the treatment of patients with immune thrombocytopenia (ITP) since the late 1980s. It is a drug that is inexpensive and well tolerated, but unfortunately, it is underused worldwide due to the lack of information regarding its
Autor:
Glenda Feldberg, Janaína B.S. Ricciardi, Alessandro R. Zorzi, Marina P. Colella, Gabriela G. Yamaguti‐Hayakawa, Margareth C. Ozelo
Publikováno v:
Haemophilia : the official journal of the World Federation of Hemophilia.
Autor:
Alessandra N L Prezotti, Paula Ribeiro Villaça, Debora M C Rocha, Maria P S V Orletti, Christiane Lourenço, Gabriela G Yamaguti Hayakawa, Margareth C Ozelo
Publikováno v:
Blood. 140:57-58
Autor:
Margareth C. Ozelo, Lucia H. Siqueira, Brooke Snetsinger, Gabriela G Yamaguti-Hayakawa, Michael J. Rauh, Samuel de Souza Medina, Fernando Ferreira Costa, Bruno Kosa Lino Duarte
Publikováno v:
British Journal of Haematology. 186:724-734
The mechanisms by which patients with RUNX1 familial platelet disorder with propensity to myeloid malignancies (FPDMM) develop myeloid malignancies (MM) are not fully understood. We report the results of targeted next-generation sequencing on three p
Autor:
S. A. de Lima Montalvão, Joyce M. Annichinno-Bizzacchi, M.C. Fernandes, Stephany Cares Huber, H.J. Aguiari, Priscila Soares Elidio, G. Yamaguti, Marcos Paulo Colella, L.D. Miranda, S.M. Soares, E. de Paula, Fernanda Andrade Orsi, A.P. Francisco
Publikováno v:
Thrombosis research. 197
Autor:
Monica De Carvalho Alcantara, Mohamed Aabdien, Craig Edward Devoe, Gabriela G Yamaguti Hayakawa, Rui Nakamura, John Christopher Polanco Santana, Cristina Pires Camargo, Bayarmagnai Maggie Munkhjargal, Vinicius Andreoli Schoeps, Igor D. Bandeira, Daniela Regina Brandão Tavares, Daniela Anamaria Hosseyni, Rania Abdelaziz Ibrahim, Augusto Cesar de Andrade Mota, Sonja Salandy, Weitao Chen
Publikováno v:
Principles and Practice of Clinical Research Journal. 5
Background and Aims: Myocardial Injury after Noncardiac Surgery (MINS) is a broader term that includes not only perioperative myocardial infarction but also other prognostically significant myocardial injuries due to ischemia, within 30 days after no